Indisulam: An anticancer sulfonamide in clinical development

Expert Opinion on Investigational Drugs

Volumn 12, Issue 2, 2003, Pages 283-287

  Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anticancer agent; Carbonic anhydrase inhibitor; Cell cycle arrest; G1 phase; Sulfonamide

Indexed keywords

4 METHOXYBENZENESULFONAMIDE; 4 METHYLBENZENESULFONAMIDE; AMIDE; AMYLOID PRECURSOR PROTEIN; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTITHYROID AGENT; ANTIVIRUS AGENT; BENZENE DERIVATIVE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE INHIBITOR; CYCLIN A; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DIURETIC AGENT; DRUG METABOLITE; FLUOROURACIL; INDISULAM; INDOLE DERIVATIVE; MATRIX METALLOPROTEINASE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; NITRILE; PLATINUM; PROTEIN P53; RETINOBLASTOMA PROTEIN; SULFONAMIDE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BONE MARROW SUPPRESSION; CELL CYCLE; CELL CYCLE G1 PHASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG RESEARCH; DRUG SYNTHESIS; ENZYME INHIBITION; EUROPE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NEUTROPENIA; NONHUMAN; NONLINEAR SYSTEM; PHYSIOLOGY; REVIEW; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; SULFONAMIDES; TECHNOLOGY, PHARMACEUTICAL;

EID: 0037315480     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.2.283     Document Type: Review

References (25)

1. CASINI A, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Sulfonamides and sulfonylated derivatives as anticancer agents. Curr. Cancer Drug Targets (2002) 2:55-75.
2. OWA T, NAGASU T: Novel sulphonamide derivatives for the treatment of cancer. Expert Opin. Ther. Patents (2000) 10:1725-1740.
3. SUPURAN CT, BRIGANTI F, TILLI S, CHEGWIDDEN WR, SCOZZAFAVA A: Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg. Med. Chem. (2001) 9:703-714.
4. OWA T, YOSHINO H, OKAUCHI T et al.: Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle. J. Med. Chem. (1999) 42:3789-3799.
5. OWA T, OKAUCHI T, YOSHIMATSU K et al.: A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:1223-1226.
6. OWA T, YOSHINO H, OKAUCHI T et al.: Synthesis and biological evaluation of N-(7-Indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents. Bioorg. Med. Chem. Lett. (2002) 12:2097-2100.
7. OWA T, YOKOI A, YAMAZAKI Y, YOSHIMATSU K, YAMORI T, NAGASU T: Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J. Med. Chem. (2002) 45:4913-4922.
8. OZAWA Y, SUGI NH, NAGASU T et al.: E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. Eur. J. Cancer (2001) 37:2275-2282.
9. FUKUOKA K, USUDA J, IWAMOTO Y et al.: Mechanism of action of the novel sulfonamide anticancer agent E7070 on cell cycle progression in human non-small cell lung cancer cells. Invest. New Drugs (2001) 19:219-227.
10. YOKOI A, KUROMITSU J, KAWAI T et al.: Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol. Cancer Ther. (2002) 1:275-286.
11. VAN KESTEREN C, MATHOT R, RAYMOND E et al.: Population pharmacokinetic analysis of the novel anti-cancer agent E7070 in a Phase I study using nonlinear mixed effect modelling (NONMEM). NCI EORTC Symp. New Drugs Cancer Ther. (2000) 11 (Abstract 340).
12. VAN KESTEREN C, MATHOT R, RAYMOND E et al.: Population pharmacokinetics of the novel anticancer agent E7070 during four Phase I studies: Model building and validation. J. Clin. Oncol. (2002) 19:4065-4073.
13. VAN DEN BONGARD D H, PLUEM D, ROSING H et al.: Metabolism and excretion of E7070 after intravenous administration to cancer patients. Proc. Am. Soc. Clin. Oncol. (2001) 20 (Abstract 371).
14. DITTRICH C, DUMEZ H, CALVERT H et al.: Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single iv infusion, weekly x 4, q 6 weeks. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 3875).
15. DROZ JP, ROCHE H, ZANETTA S et al.: Phase I trial of five-days continuous infusion E7070 [N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] in patients (pts) with solid tumors. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 3876).
16. PUNT CJA, FUMOLEAU P, WALLE BVD et al.: Phase I and pharmacokinetic (PK) study of E7070, a novel sulphonamide, given daily x 5 every 3 weeks as a 1-hour intravenous infusion in patients (pts) with advanced solid tumors. Proc. Am. Assoc. Cancer Res. (2000) 41 (Abstract 3877).
17. PUNT CJ, FUMOLEAU P, VAN DE WALLE B, FABER MN, RAVIC M, CAMPONE M: Phase I and pharmacokinetic study of E7070, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-early clinical studies group (ECSG). Ann. Oncol. (2001) 12:1289-1293.
18. VAN KESTEREN C, MATHOT RA, RAYMOND E et al.: Population pharmacokinetics of the novel anticancer agent E7070 during four Phase I studies: Model building and validation. J. Clin. Oncol. (2002) 20:4065-4073.
19. RAYMOND E, TEN BOKKEL HUINIK WW, TAIEB J et al.: Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor as an one hour infusion every three weeks in patients with advanced cancer. J. Clin. Oncol. (2002) 20:3508-3521.
20. MAINWARING PN, VAN CUTSEM E, VAN LAETHEM JL et al.: A multicentre randomised Phase II study of E7070 in patients with colorectal cancer who have failed 5-fluorouracil-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 611).
21. TALBOT D, NORBURY C, SLADE M et al.: Phase II and pharmacodynamic study of E7070 in patients with Non-Small Cell Lung Cancer (NSCLC) who have failed platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol. (2002) 21 (Abstract 1306).
22. VAN KESTEREN C, BEIJNEN JH, SCHELLENS JH: E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anti-Cancer Drugs (2002) 13:989-997.
23. SUPURAN CT, SCOZZAFAVA A: Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin. Ther. Patents (2000) 10:575-600.
24. SUPURAN CT, SCOZZAFAVA A: Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin. Ther. Patents (2002) 12:217-242.
25. CHEGWIDDEN WR, SPENCER IM, SUPURAN CT: The roles of carbonic anhydrase isozymes in cancer. In: Gene Families: Studies of DNA, RNA, Enzymes and Proteins. G Xue, Y Xue, Z Xu, R Holmes, GL Hammond, HA Lim (Eds), World Scientific, Singapore (2001):157-170.